The impact of multiparametric MRI on the staging and management of patients with suspected or confirmed ovarian cancer

Imperial College London (UK)0 个研究点目标入组 648 人开始时间: 2015年11月30日最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•1. Written (signed and dated) informed consent* prior to mpMRI scan^ and judged capable of co-operating with study requirements during treatment and follow-up
•2. Aged 18 years or over
•3. Suspected ovarian, fallopian tube or primary peritoneal cancer. This can be contingent on imaging findings (either on ultrasound or CT) and/or a Risk Malignancy Index Score (RMI) greater than 250
•4. Being considered for up-front surgery or for interval debulking surgery following neoadjuvant chemotherapy (after 3 to 5 cycles) via the NHS Cancer Pathway”
•5. Considered fit for surgery (by MDT or patient’s surgeon)
•*A patient can be enrolled based on verbal consent with written consent to be obtained prior to the mpMRI scan

•1. Known contraindication to MRI (e.g. claustrophobia, ferrous implants, cardiac pacemaker, inability to lie flat)
•2. Known pregnancy
•3. Medical or psychiatric illness that renders the patient unsuitable or unable to give informed consent
•4. Unable to undergo a CT scan with IV contrast due to allergy, renal failure or any other cause

发起方

Imperial College London (UK)